Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease

Kidney International, Supplement

Volumn 67, Issue 95, 2005, Pages

  Lindberg, Jill S ^a,b  

^a New Orleans Nephrology Associates   (United States)

^b New Orleans Nephrology Associates   (United States)

Author keywords

Ca x P product; Calcimimetics; Cinacalcet HCl; PTH; Secondary hyperparathyroidism; Serum calcium; Serum phosphorus

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D; PLACEBO; R 568; ANILINE DERIVATIVE; N (2 CHLOROPHENYLPROPYL) 1 (3 METHOXYPHENYL)ETHYLAMINE; N-(2-CHLOROPHENYLPROPYL)-1-(3-METHOXYPHENYL)ETHYLAMINE; NAPHTHALENE DERIVATIVE;

ARTICLE; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; HEALTH CARE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; MINERAL METABOLISM; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; DRUG TOLERABILITY; NAUSEA; PATIENT CARE; VOMITING; CHRONIC KIDNEY FAILURE; DRUG POTENTIATION; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANILINE COMPOUNDS; CALCIUM; HUMANS; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 24944511675     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09505.x     Document Type: Article

References (21)

1. LINDBERG JS, MOE SM: Production metabolic bone disease. Semin Nephrol 24:1-2, 2004
2. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines on bone metabolism and disease. Am J Kidney Dis 42(Suppl 3):1-2001, 2003
3. LOCATELLI F, CANNATA-ANDIA JB, DRUEKE TB, et al: Management of disturbances of calcium and phosphate metabolism and chronic renal insufficiency with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant 17:723-731, 2002
4. GOODMAN WG: Calcimimetic agents and secondary hyperparathyroidism treatment and prevention. Nephrol Dial Transplant 17:1-6, 2002
5. TORRES PU: Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 19(Suppl 5):27-33, 2004
6. WADAM M, NAGANO N, FURUYA Y, et al: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58, 2000
7. WADAM M, FURUYA Y, SAKIYAMA J, et al: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983, 1997
8. WADAM M, FURUYA Y, SAKIYAMA J, et al: NPS R-568 halts or reverses osteoitis fibrosis in uremic rats. Kidney Int 53:448-453, 1997
9. ANTONSEN JE, SHIROUD DJ, ANDRESS DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53:223-227, 1998
10. GOODMAN WG, FRAVO JM, GOODKIN DA, et al: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445, 2000
11. FOX J, LOWES H, PETTY BA, et al: NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290:473-479, 1999
12. GOODMAN WG, HALADIK GA, TURNER SA, et al: Calcimimetic agent AMG 073 lowers parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002
13. LINDBERG JS, MOE SM, GOODMAN WG, et al: Calcimimetic AMG 073 reduces parathyroid hormone in calcium x phosphate in secondary hyperparathyroidism. Kidney Int 63:248-254, 2003
14. DRUEKE TB, CUNNINGHAM J, GOODMAN WG, et al: Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764A, 2001
15. CUNNINGHAM J, HOLZER H, REICHEL H, et al, on behalf of the AMG 073 study groups. IV Symposium Avances en Osteodistrofia Renal Oveido, June 6-7, 2002
16. DE FRANCISCO ALM, SURANYI M, CUNNINGHAM J, et al: Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism, results of a European/Australian phase 3 study. J Am Soc Nephrol 14:461A, 2003
17. BRACH GA, MARTIN KJ, DE FRANCISCO ALM, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1520-1529, 2004
18. LINDBERG JS, CULLETON B, WONG G, et al: Phase 3 experience with cinacalcet HCl and hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 14:36A, 2003
19. MOE SM, SPRAG SM, ADLER S, et al: Two-year treatment with the calcimimetic AMG 073 in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:572A, 2002
20. HARRIS R, PADHI D, SALFI M, et al: Pharmacokinetics (PK), pharmacodynamics (PD), and safety of daily administration of cinacalcet HCl up to 300 mg in chronic kidney disease (CKD) patients on hemodialysis (HD). J Am Soc Nephrol 14:462A, 2003
21. GOODMAN WG: Calcium-sensing receptors. Semin Nephrol 24:17-24, 2004